Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal clinically important difference module: summary, recommendations, and research agenda.
Wells G, Anderson J, Beaton D, Bellamy N, Boers M, Bombardier C, Breedveld F, Carr A, Cranney A, Dougados M, Felson D, Kirwan J, Schiff M, Shea B, Simon L, Smolen J, Strand V, Tugwell P, van Riel P, Welch VA. Wells G, et al. Among authors: schiff m. J Rheumatol. 2001 Feb;28(2):452-4. J Rheumatol. 2001. PMID: 11246695 Review. No abstract available.
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Wells G, et al. Among authors: schiff m. Ann Rheum Dis. 2009 Jun;68(6):954-60. doi: 10.1136/ard.2007.084459. Epub 2008 May 19. Ann Rheum Dis. 2009. PMID: 18490431 Free PMC article.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Furst DE, et al. Among authors: schiff mh. J Rheumatol. 2003 Dec;30(12):2563-71. J Rheumatol. 2003. PMID: 14719195 Clinical Trial.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Furst DE, et al. Among authors: schiff mh. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. Ann Rheum Dis. 2008. PMID: 19022808 No abstract available.
706 results